Journal Article

Arterial hypertension—clinical trials update 2024

Böhm, Michael, Lauder, Lucas, Mahfoud, Felix, Götzinger, Felix, Tokcan, Mert

2024

Overview

Arterial hypertension remains the most important modifiable cardiovascular risk factor for morbidity and mortality worldwide. This review summarizes and discusses major clinical trials published in 2023 and early 2024 in hypertension research. These trials include new epidemiological data, studies investigating the impact of blood pressure cuff size on blood pressure measurements, benefits of salt substitutes, and novel antihypertensive treatment options, including pharmacotherapy and bariatric surgery in patients with obesity. This summary reviews the major clinical trials published in 2023 and early 2024. AHT arterial hypertension, BP blood pressure, HR hazard ratio, OBP office blood pressure, PRA plasma renin activity, SBP systolic blood pressure. This summary reviews the major clinical trials published in 2023 and early 2024. AHT – arterial hypertension, BP – blood pressure, HR – hazard ratio, OBP – office blood pressure, PRA – plasma renin activity, SBP – systolic blood pressure.

• Publisher: Springer Nature Singapore,Nature Publishing Group
• Subject: Antihypertensive Agents - therapeutic use / Antihypertensives / Blood pressure / Blood Pressure - drug effects / Cardiovascular disease / Chloride / Clinical trials / Clinical Trials as Topic / Diabetes / Diet / Drug therapy / Gastrointestinal surgery / Geriatrics/Gerontology / Health Promotion and Disease Prevention / Health risks / High density lipoprotein / Humans / Hypertension / Hypertension - drug therapy / Hypertension - therapy / Internal Medicine / Lipoproteins / Medicine / Medicine & Public Health / Middle age / Morbidity / Mortality / Obesity / Obstetrics/Perinatology/Midwifery / Potassium / Public Health / Review Article / Salt / Sodium / Womens health